Trial Profile
A double-blind, randomized phase II study of once daily versus twice daily PTK787/ZK 222584 treatment in patients with advanced, previously treated metastatic adenocarcinoma of the colon or rectum
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Apr 2022
Price :
$35
*
At a glance
- Drugs Vatalanib (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Sponsors Bayer HealthCare Pharmaceuticals
- 07 Apr 2022 Status changed from recruiting to completed.
- 06 Jul 2012 New trial record